No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

12/2

Novartis

PTC Therapeutics

Small molecule

(votoplam)

alternative splicing technology

platform

Huntingtin / oral route

Huntington disease

Phase II

2,900

2

12/18

Merck

Jiangsu Hansoh

Pharmaceutical

Small molecule

(HS-10535)

GLP-1R / oral route

Unspecified

Preclinical

2,012

3

12/19

Astellas Pharma

Sangamo

Therapeutics

neurotropic adeno-associated

virus (AAV) capsid

(STAC-BBB)

undisclosed gene / IV route

unspecified neurological

diseases

Discovery

1,320

4

12/3

Takeda

Keros

Therapeutics

Fusion protein

(elritercept)

TGF-beta / SC route

myelodysplastic Syndrome (MDS), myelofibrosis (MF)

Phase II

1,300

5

12/29

Ideaya Biosciences

Jiangsu Hengrui

Medicine

DLL3 Topo-I-Payload ADC
(SHR-4849)

DNA Topoisomerase I Inhibitor

solid tumors,

small cell lung cancer,

neuroendocrine tumors

Phase I

1,045

6

12/3

GSK

Duality Biologics

antibody-drug conjugate (ADC)

(DB-1324)

-

gastrointestinal cancer

Preclinical

1,005

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

12/13

AbbVie

Nimble Therapeutics

Oral C5 Inhibitor

Type : Peptide

Target : Complement C5

Indication : Myasthenia Gravis

Stage : Preclinical

200

Oral IL-23R Inhibitor

Type : Peptide

Target : Interleukin 23 Receptor

Indication : Psoriasis

Stage : Preclinical

3

12/3

Intas Pharmaceuticals

Coherus BioSciences

pegfilgrastim

Type : Recombinant Protein

Target : Granulocyte Colony Stimulating Factor Receptor

Indication : Febrile Neutropenia, Radiation Induced Myelosuppression

Stage : Marketed

558.4